Luminance Biosciences

Luminance Biosciences is a clinical-stage biotechnology company dedicated to developing innovative topical therapies for dermatological and inflammatory diseases. The company's lead program, LMN-001, is a potent and selective Janus kinase (JAK) inhibitor specifically designed for local delivery to treat conditions such as atopic dermatitis while minimizing systemic exposure. By utilizing advanced formulation technologies, Luminance aims to provide safer and more effective alternatives to existing systemic treatments that often carry significant side-effect risks. The company is led by a management team with deep expertise in dermatology drug development and is currently advancing its pipeline through mid-stage clinical trials.